Editorial: Immune-Related Adverse Events for Patients With Lung Cancer

Editorial: Immune-Related Adverse Events for Patients With Lung Cancer

Bibliographic Details
Main Authors:	Ruoning Yang, Haiyang Wang, Xiaomeng Yin, Benjamin Frey, Udo S. Gaipl, Hubing Shi, Xuelei Ma
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Oncology
Subjects:	editorial lung cancer immunotherapy immune-related adverse events (IRAEs) management pathogenesis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.898576/full

Similar Items

Editorial: Immune-related adverse events for patients with lung cancer-volume II
by: Yusha Wang, et al.
Published: (2023-11-01)

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
by: Ben Ponvilawan, et al.
Published: (2024-03-01)

Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma
by: Bożena Cybulska-Stopa, et al.
Published: (2022-05-01)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
by: Raju Vaddepally, et al.
Published: (2022-03-01)

Relationship between immune‐related adverse events and treatment effectiveness in extensive disease small cell lung cancer
by: Keiki Yokoo, et al.
Published: (2023-08-01)

Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series
by: Antonella Laria, et al.
Published: (2021-08-01)

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer
by: Taiseer Al-Rajabi, et al.
Published: (2023-09-01)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
by: Gunther Glehr, et al.
Published: (2022-09-01)

The role of T cells in tumor radiotherapy combined with immunotherapy and gastrointestinal adverse events
by: SHI Xiaolin, et al.
Published: (2021-02-01)

A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients
by: Shaohua CUI, et al.
Published: (2023-04-01)

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
by: Adrian Chye, et al.
Published: (2022-07-01)

Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
by: Ni Zhao, et al.
Published: (2022-08-01)

Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
by: Ni Zhao, et al.
Published: (2022-12-01)

Adverse Events of Oncologic Immunotherapy and Their Management
by: Fedricker Diane Barber
Published: (2019-01-01)

Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II
by: Yueyi Li, et al.
Published: (2023-07-01)

Tissue-resident memory T cells in immune-related adverse events: friend or foe?
by: Robin Reschke, et al.
Published: (2023-12-01)

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
by: Hamid Mithoowani, et al.
Published: (2022-03-01)

Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes
by: Charline Lafayolle de la Bruyère, et al.
Published: (2021-05-01)

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
by: Alexander Batista-Duharte, et al.
Published: (2023-05-01)

Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells
by: Marianne Gazzano, et al.
Published: (2022-12-01)

Rheumatological Adverse Events Following Immunotherapy for Cancer
by: Ioana Cretu, et al.
Published: (2022-01-01)

Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
by: Betul Ibis, et al.
Published: (2023-06-01)

Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases
by: Jean-Matthieu L’Orphelin, et al.
Published: (2021-09-01)

Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy
by: Jeong Uk Lim, et al.
Published: (2021-08-01)

Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review
by: Ranferi Ocaña-Guzmán, et al.
Published: (2023-08-01)

CXCR5+CD8 T cells: Potential immunotherapy targets or drivers of immune-mediated adverse events?
by: Christi N. Turner, et al.
Published: (2022-10-01)

Adverse Events as End Points: The Need to Account for Both Sides of the Same Coin
by: Felipe Aizpuru
Published: (2017-04-01)

Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study
by: Francoise Difoum, et al.
Published: (2023-07-01)

Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
by: Ye Tao, et al.
Published: (2023-05-01)

A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer
by: Yue Hu, et al.
Published: (2023-04-01)

The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database
by: Huaju Yang, et al.
Published: (2023-11-01)

Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy
by: Wei-Ting Hu, et al.
Published: (2023-03-01)

Technical Aspects of Lung Transplantation: Adverse Events and Circumstances
by: Do Hyung Kim
Published: (2022-08-01)

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
by: Mona A. Marie, et al.
Published: (2022-12-01)

Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice
by: Mitchell S. von Itzstein, et al.
Published: (2024-04-01)

Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies
by: Xinyu Guo, et al.
Published: (2023-04-01)

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
by: Agnese Paderi, et al.
Published: (2021-02-01)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
by: Yanting Zhou, et al.
Published: (2023-06-01)

A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy
by: Rose Parisi, et al.
Published: (2023-01-01)

Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Management of adverse events
by: Jaume Mora, et al.
Published: (2023-01-01)